MC
DRNA

Moors & Cabot’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Moors & Cabot’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,073
Closed -$227K – 932
2021
Q2 		$227K Buy
+6,073
New +$186K 0.02% 684
2020
Q3 		– Sell
-8,100
Closed -$206K – 753
2020
Q2 		$206K Buy
+8,100
New +$174K 0.02% 574

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Moors & Cabot's DRNA Position: Q3 2021 in Review

Moors & Cabot sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 6,073 shares — an estimated $227K sold.

Moors & Cabot first reported a position in DRNA in Q2 2020 and held it in 2 quarters. The position peaked at $227K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Moors & Cabot reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Moors & Cabot sold 6,073 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $227K.
  • Moors & Cabot first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 2 quarters.
  • Moors & Cabot's Dicerna Pharmaceuticals, Inc. position peaked at $227K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Moors & Cabot's 13F filing for Q3 2021, filed 5 Nov 2021.